The IGNITE Pharmacogenetics Working Group: An Opportunity for Building Evidence with Pharmacogenetic Implementation in a Real-World Setting

Author:

Cavallari LH1,Beitelshees AL2,Blake KV3,Dressler LG4,Duarte JD1,Elsey A1,Eichmeyer JN5,Empey PE6,Franciosi JP7,Hicks JK8,Holmes AM9,Jeng LJB10,Lee CR11,Lima JJ3,Limdi NA12,Modlin J5,Obeng AO13,Petry N14,Pratt VM.15,Skaar TC16,Tuteja S17,Voora D18,Wagner M5,Weitzel KW1,Wilke RA19,Peterson JF20,Johnson JA1

Affiliation:

1. Department of Pharmacotherapy and Translational Research; University of Florida; Gainesville Florida USA

2. Department of Medicine; University of Maryland; Baltimore Maryland USA

3. Biomedical Research Department; Nemours Children's Specialty Care; Jacksonville Florida USA

4. Personalized Medicine and Pharmacogenetics Program; Mission Health; Asheville North Carolina USA

5. Department of Oncology; St. Luke's Mountain States Tumor Institute; Boise Idaho USA

6. Department of Pharmacy and Therapeutics; Center for Clinical Pharmaceutical Sciences; University of Pittsburgh School of Pharmacy; Pittsburgh Pennsylvania USA

7. Biomedical Research Department; Nemours Children's Specialty Care; Orlando Florida USA

8. Division of Population Science; DeBartolo Family Personalized Medicine Institute; Moffitt Cancer Center; Tampa Florida USA

9. Department of Health Policy and Management; Richard M. Fairbanks School of Public Health; Indiana University - Purdue University; Indianapolis Indiana USA

10. Departments of Medicine, Pathology, and Pediatrics; University of Maryland School of Medicine; Baltimore Maryland USA

11. Division of Pharmacotherapy and Experimental Therapeutics; Eshelman School of Pharmacy; University of North Carolina at Chapel Hill; Chapel Hill North Carolina USA

12. Department of Neurology; University of Alabama; Birmingham Alabama USA

13. Charles Bronfman Institute for Personalized Medicine; Icahn School of Medicine at Mount Sinai; New York New York USA

14. Department of Pharmacy Practice; North Dakota State University; Fargo North Dakota USA

15. Department of Medical and Molecular Genetics; Indiana University School of Medicine; Indianapolis Indiana USA

16. Department of Medicine, Division of Clinical Pharmacology; Indiana University School of Medicine; Indianapolis Indiana USA

17. Division of Translational Medicine and Human Genetics; Perelman School of Medicine at the University of Pennsylvania; Philadelphia Pennsylvania USA

18. Center for Applied Genomics & Precision Medicine, Department of Medicine; Duke University; Durham North Carolina USA

19. Department of Internal Medicine; University of South Dakota; Sioux Falls South Dakota USA

20. Departments of Biomedical Informatics and Medicine; Vanderbilt University Medical Center; Nashville Tennessee USA

Funder

National Institutes of Health

University of Florida

University of Maryland Medical Center and University of Maryland School of Medicine Program for Personalized and Genomic Medicine

Office of the Vice Chancellor for Research, University of Illinois at Chicago

American Society of Health System Pharmacists

Penn Center for Precision Medicine at the Perelman School of Medicine at the University of Pennsylvania

University of Alabama

Birmingham Health Service Foundations' General Endowment Fund

Indiana University Health

Indiana University School of Medicine Strategic Research Initiative

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Reference6 articles.

1. CPIC: Clinical pharmacogenetics implementation consortium of the pharmacogenomics research network;Relling;Clin. Pharmacol. Ther.,2011

2. A new initiative on precision medicine;Collins;N. Engl. J. Med.,2015

3. The IGNITE network: a model for genomic medicine implementation and research;Weitzel;BMC. Med. Genomics.,2016

4. Clinical pharmacogenetics implementation consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update;Scott;Clin. Pharmacol. Ther.,2013

5. Prospective clinical implementation of CYP2C19-genotype guided antiplatelet therapy after PCI: a multi-site investigation of MACE outcomes in a real-world setting;Cavallari;Circulation.,2016

Cited by 72 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Clinical Genetics and Referrals;Genomics in the Clinic;2024

2. Impact of Pharmacogenomics in Clinical Practice;Pharmaceuticals;2023-11-13

3. Experience and expectations of pharmacogenetic tests in France;Therapies;2023-07

4. Pharmacogenetics of Antiplatelet Therapy;Annual Review of Pharmacology and Toxicology;2023-01-20

5. Medication reconciliation to support pharmacogenomics implementation;Annals of Translational Medicine;2022-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3